Literature DB >> 7308280

Pharmacokinetics of intravenous and oral isosorbide - 5 - mononitrate.

U Abshagen, G Betzien, R Endele, B Kaufmann.   

Abstract

The pharmacokinetics of isosorbide-5-mononitrate (IS-5-MN) has been studied in two groups of healthy volunteers after oral (n = 20) and intravenous (n = 11) administration of 20 mg, which had previously been proved to be as effective as 20 mg sustained-release isosorbide dinitrate (ISDN). IS-5-MN in serum was measured by gas chromatography using capillary columns. The kinetic calculations were carried out with a newly developed model, which assumes a virtual volume of distribution dependent on time. IS-5-MN is rapidly (invasion half-life 4.1 min) and completely absorbed from the gastro-intestinal tract without any first pass metabolism. The maximum concentration of 480 micrograms/l was reached 1.2 h after oral administration of 20 mg. The substance was distributed throughout the total body water (distribution coefficient: 0.62), and was eliminated with a terminal t1/2 of 4.1 and 4.6 h after oral and intravenous administration, respectively. Total body clearance was 115ml/min. Thus, IS-5-MN is unlike ISDN with respect to the absence of first-pass metabolism and an 8-times longer half-life. The consequences for therapy are discussed.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7308280     DOI: 10.1007/bf00618777

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  11 in total

Review 1.  Recent views on the mechanisms of nitrate ester metabolism.

Authors:  M H Litchfield
Journal:  Drug Metab Rev       Date:  1973       Impact factor: 4.518

2.  Biotransformation of isosorbide dinitrate in humans.

Authors:  W H Down; L F Chasseaud; R K Grundy
Journal:  J Pharm Sci       Date:  1974-07       Impact factor: 3.534

3.  [Pharmacodynamics, pharmacokinetics and metabolism of isosorbide nitrates in the awake dog].

Authors:  K Dietmann; G Sponer; E Voss
Journal:  Med Welt       Date:  1981-04-07

4.  [Hemodynamic changes at rest and during stress following isosorbide-5-mononitrate therapy in patients with coronary disease].

Authors:  J Isbary; W Doering; B Wauer; H Greding; E König
Journal:  Med Welt       Date:  1981-04-07

5.  Systemic and coronary vascular effects of the 2- and the 5-mononitrate esters of isosorbide.

Authors:  R L Wendt
Journal:  J Pharmacol Exp Ther       Date:  1972-03       Impact factor: 4.030

6.  [Comparison of the anti-angina effect and effect duration of isosorbide dinitrate, isosorbide-2-mononitrate (IS-2-MN) and isosorbide-5-mononitrate (IS-5-MN)].

Authors:  N Reifart; F Reifart; M Kaltenbach; W D Bussmann
Journal:  Med Welt       Date:  1981-04-07

7.  First data on effects and pharmacokinetics of isosorbide-5-mononitrate in normal man.

Authors:  U Abshagen; S Spörl-Radun
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

8.  Pharmacokinetics of isosorbide dinitrate after intravenous infusion in human subjects.

Authors:  T Taylor; L F Chasseaud; E Doyle; A Darragh; D A O'Kelly; D Fitzgerald
Journal:  Biopharm Drug Dispos       Date:  1980 Jan-Mar       Impact factor: 1.627

9.  Vascular effects of the dinitrate and moninitrate esters of isosorbide, isomannide and isoidide.

Authors:  M G Bogaert; M T Rosseel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1972       Impact factor: 3.000

10.  Effects and pharmacokinetics of isosorbide dinitrate in normal man.

Authors:  S Spörl-Radun; G Betzien; B Kaufmann; V Liede; U Abshagen
Journal:  Eur J Clin Pharmacol       Date:  1980-10       Impact factor: 2.953

View more
  23 in total

Review 1.  Development of long-acting nitrate delivery systems.

Authors:  U E Jonsson
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 2.  Pharmacokinetics of various preparations of organic nitrates.

Authors:  J P Kampmann
Journal:  Drugs       Date:  1987       Impact factor: 9.546

3.  The effect of food on the absorption of slow-release isosorbide-5-mononitrate tablets.

Authors:  A H Thomson; S H Miller; S T Green; B Whiting
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

4.  Relationship between pharmacokinetics and hemodynamic tolerance to isosorbide-5-mononitrate.

Authors:  F Wagner; F Siefert; D Trenk; E Jähnchen
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

5.  Pharmacokinetics of isosorbide-5-nitrate during haemodialysis and peritoneal dialysis.

Authors:  J Evers; R Bonn; A Boertz; W Cawello; V Luckow; M Fey; F Aboudan; H A Dickmans
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

6.  Experience of long term treatment and different dosage regimens of isosorbide 5-mononitrate.

Authors:  M Meffert; I M Paeckelmann
Journal:  Drugs       Date:  1987       Impact factor: 9.546

7.  Dose-dependent headache response and dilatation of limb and extracranial arteries after three doses of 5-isosorbide-mononitrate.

Authors:  H K Iversen; T H Nielsen; K Garre; P Tfelt-Hansen; J Olesen
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

8.  Pharmacokinetics of isosorbide dinitrate and its mononitrate metabolites after intravenous infusion.

Authors:  Y Santoni; A Iliadis; J P Cano; R Luccioni; Y Frances
Journal:  J Pharmacokinet Biopharm       Date:  1986-02

9.  Pharmacokinetics of isosorbide-5-nitrate in renal failure.

Authors:  J Evers; B Krakamp; W Klimkait; H A Dickmans; J Maddock; V Luckow; W Cawello; M Weiss
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 10.  Clinical pharmacokinetics of organic nitrates.

Authors:  M G Bogaert
Journal:  Clin Pharmacokinet       Date:  1983 Sep-Oct       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.